BillionToOne, Inc. Class A BLLN

BillionToOne has delivered a strong year to date gain, which puts fresh focus on whether the current share price lines up with the cash the business is expected to generate over time. With the valuation lens firmly on its cash flows, you need to ask whether the recent move reflects sustainable fundamentals or simply enthusiasm. The stock is up 30.0% year to date, which raises the stakes on whether today's valuation is adequately supported by the cash it can produce. The business model, which...

Key TakeawaysNo-Headline Rally: BillionToOne stock jumped 12% to $116 on Tuesday, September 22, without a company release, stretching a run that began near $100 on September 14. Insiders Took Profits: The CEO and general counsel sold ~60K shares for ~$6.

BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.

When a caller asked for the Mad Money host’s take on BillionToOne, Inc. (NASDAQ:BLLN) during the lightning round on August 26, Jim Cramer commented: You know, we did a big piece on this, and we decided, you know, it’s a pretty darn good company. I know it’s expensive, but you know what? Look, genetic diagnostic, […]

BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal. This is the first prospective NIPT study conducted in an intended-use screening population with near-complete pregnancy outcome ascertainmen

BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal. This is the first prospective NIPT study conducted in an intended-use screening population with near-complete pregnancy outcome ascertainmen

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

BillionToOne (BLLN) is back in focus after its August 5 update, when the company reported second quarter 2026 results and reaffirmed its full-year revenue outlook in the mid US$400 million range. See our latest analysis for BillionToOne. The recent earnings beat and reiterated 2026 revenue guidance have been met with strong buying interest, with BillionToOne’s share price return of 61.4% over 90 days and 68.0% year to date signaling firm positive momentum. If BillionToOne’s move has caught...

Moby summary of BillionToOne, Inc.'s Q2 2026 earnings call

BillionToOne Inc (BLLN) posts strong Q2 with record revenue, expanding margins, and strategic momentum in oncology and prenatal testing.

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026. Financial Highlights: Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 6